BioElectronics Corporation Reports Q3 Earnings
BioElectronics Corporation (OTC: BIEL) reported a remarkable 463% year-over-year revenue growth for the third quarter of 2021, leading to profitability. Sales revenue for the nine months ended September 30, 2021, reached substantially higher levels compared to the previous year. The firm also noted a deferred revenue of $256,398, indicating future sales potential. Expansion efforts include the launch of KT Recovery+ Wave in the UK and partnerships in Australia, Korea, and Bangladesh. The company is also advancing its brain stimulation project in collaboration with Binghamton University.
- 463% year-over-year revenue growth for Q3 2021.
- Profitability achieved in Q3 2021.
- Deferred revenue of $256,398 indicating future sales.
- Expansion into the UK market with KT Recovery+ Wave.
- Strong demand reported for RecoveryRx in Australia.
- Upcoming product launch in Korea expected in Spring 2022.
- None.
Year over Year Revenue Growth Exceeds
FREDERICK, MARYLAND, Nov. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL) announces a
Keeping in line with BIEL’s impressive year-over-year growth, the nine months ended September 30, 2021 sales were
KT Health, LLC has received its initial order to launch its KT Recovery+ WaveTM in the United Kingdom and intends to continue expansion into other markets.
The Company continues making progress on international sales. Our sales partner in Australia, LMT Surgical Party, Ltd, is reporting strong demand and excellent clinical outcomes with the RecoveryRx product. Our sales partner in Korea is preparing to receive their first order with an expected product launch date in the spring of 2022. Our distributor in Bangladesh has resumed full operations following Covid19 shutdowns in Bangladesh and has placed an order for delivery in the first quarter of 2022. The sales team continues discussions with several firms that have an established presence in the consumer health space, to expand distribution in Europe and the MENA (Middle East and North Africa) region. The sales team is also actively seeking an OEM partner for a wound pain product development partnership.
The Research and Development team is expanding its efforts regarding the brain stimulation project by collaborating with the Clinical Science and Engineering Research Lab at Binghamton University under the guidance of Ken McLeod, Ph.D. The vision behind this research undertaking is to develop and optimize PSWT technology that will be capable of serving as a therapeutic intervention for psychological disorders such as depression and anxiety.
Two major lenders continue to neither collect nor accrue interest on their notes and no additional stock was issued during the 3rd quarter. It is likely, but not certain, that these lenders will continue to forgo interest at least through the 2nd quarter of 2022 to help offset increased supply and shipping costs caused by global shortages due to the pandemic.
The team at BioElectronics is looking forward to continuing to improve the financial health of the Company and the resulting increase in shareholder value.
About BioElectronics: BioElectronics Corporation is a leader in non-invasive electroceuticals and the manufacturer of industry leading disposable, drug-free, pain therapy devices for the over-the-counter treatment of back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative pain and wound care. For more information, visit www.bielcorp.com
Disclosure Certain information set forth in this email contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company’s current customer, supplier and other material agreements; and (viii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this email are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
Contact: Paul Knopick
pknopick@eandecommunications.com
940.262.3584
FAQ
What were BioElectronics Corporation's Q3 2021 revenue results?
How is BioElectronics Corporation expanding its market reach?
What is the significance of the deferred revenue reported by BioElectronics?
When is the expected product launch in Korea by BioElectronics?
Is BioElectronics Corporation currently profitable?
